Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $966.50 million. The enterprise value is $1.05 billion.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 262.64 million shares outstanding. The number of shares has increased by 13.54% in one year.
| Current Share Class | 262.64M |
| Shares Outstanding | 262.64M |
| Shares Change (YoY) | +13.54% |
| Shares Change (QoQ) | +10.47% |
| Owned by Insiders (%) | 2.01% |
| Owned by Institutions (%) | 38.63% |
| Float | 257.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.35 |
| Forward PS | 4.68 |
| PB Ratio | 39.17 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.67 |
| EV / EBITDA | 102.80 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.23, with a Debt / Equity ratio of 7.96.
| Current Ratio | 2.23 |
| Quick Ratio | 1.92 |
| Debt / Equity | 7.96 |
| Debt / EBITDA | 12.87 |
| Debt / FCF | n/a |
| Interest Coverage | -0.78 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -4.26% |
| Return on Invested Capital (ROIC) | -7.83% |
| Return on Capital Employed (ROCE) | -8.33% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | -$250,348 |
| Employee Count | 181 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 1.40 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +307.22% in the last 52 weeks. The beta is 0.84, so AKBA's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +307.22% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | 2.08 |
| Relative Strength Index (RSI) | 63.82 |
| Average Volume (20 Days) | 6,576,101 |
Short Selling Information
The latest short interest is 20.05 million, so 7.64% of the outstanding shares have been sold short.
| Short Interest | 20.05M |
| Short Previous Month | 19.72M |
| Short % of Shares Out | 7.64% |
| Short % of Float | 7.79% |
| Short Ratio (days to cover) | 4.20 |
Income Statement
In the last 12 months, AKBA had revenue of $184.91 million and -$45.31 million in losses. Loss per share was -$0.21.
| Revenue | 184.91M |
| Gross Profit | 153.31M |
| Operating Income | -18.24M |
| Pretax Income | -40.44M |
| Net Income | -45.31M |
| EBITDA | 10.20M |
| EBIT | -18.24M |
| Loss Per Share | -$0.21 |
Full Income StatementBalance Sheet
The company has $113.37 million in cash and $195.60 million in debt, giving a net cash position of -$82.22 million or -$0.31 per share.
| Cash & Cash Equivalents | 113.37M |
| Total Debt | 195.60M |
| Net Cash | -82.22M |
| Net Cash Per Share | -$0.31 |
| Equity (Book Value) | 24.58M |
| Book Value Per Share | 0.09 |
| Working Capital | 112.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.81 million and capital expenditures -$51,000, giving a free cash flow of -$34.87 million.
| Operating Cash Flow | -34.81M |
| Capital Expenditures | -51,000 |
| Free Cash Flow | -34.87M |
| FCF Per Share | -$0.13 |
Full Cash Flow StatementMargins
Gross margin is 82.91%, with operating and profit margins of -9.86% and -24.51%.
| Gross Margin | 82.91% |
| Operating Margin | -9.86% |
| Pretax Margin | -24.51% |
| Profit Margin | -24.51% |
| EBITDA Margin | 5.52% |
| EBIT Margin | -9.86% |
| FCF Margin | n/a |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.54% |
| Shareholder Yield | -13.54% |
| Earnings Yield | -4.69% |
| FCF Yield | -3.61% |
Analyst Forecast
The average price target for AKBA is $6.90, which is 87.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.90 |
| Price Target Difference | 87.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 24.22% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -5.99 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.99 |
| Piotroski F-Score | 2 |
